Yescarta Demonstrates Improvement in Overall Survival Compared to Standard of Care in Lymphoma Treatment

Axicabtagene ciloleucel demonstrated a 2.5-fold increase in individuals with relapsed/refractory large B-cell lymphoma who were alive at 2 years and did not experience either cancer progression or require the need for additional cancer treatment.

Related Keywords

Switzerland ,United Kingdom ,United States ,Lugano ,Ticino ,Japan ,Israel ,Great Britain , ,European Union ,Image Credit ,Lugano Classification ,